Remarkably, in 2018, after successful clinical trials, the lutetium-177-labeled DOTATATE peptide (LutatheraTM) was approved for the first-in-class PRRT of SSTR2-positive gastroenteropancreatic and neuroendocrine tumors [9,10], whereas in 2022, PluvictoTM (Lu-177 vipivotide tetraxetan, formerly 177Lu-PSMA-617) was registered for the RLT of PSMA-positive metastatic castration-resistant prostate cancers [11]. The gene discussed is FOLH1; the disease is neuroendocrine neoplasm.